Historical position

Fidelity Investments’s Pfizer (PFE) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

FMR LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares24.90MHighest verified quarter-end share count
Quarters reported22Verified quarters with shares above zero
What happened?

FMR LLC first reported Pfizer in Q3 2016. The reported position was increased and reduced across later filings. Verified positive position history runs through Q4 2024. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2024
Sold 25.7% of the position−3.72M shares · 10.76M shares remained
Filing context

Quarter-end price $26.53

Q4 2023
Sold 13.3% of the position−1.53M shares · 10.00M shares remained
Filing context

Quarter-end price $28.79

Q2 2023
Sold 47.1% of the position−11.66M shares · 13.08M shares remained
Filing context

Quarter-end price $36.68

Q1 2023
Bought 94.5% more+12.02M shares · 24.74M shares reported after the change
Filing context

Quarter-end price $40.80

Q4 2022
Sold 40.7% of the position−8.72M shares · 12.72M shares remained
Filing context

Quarter-end price $51.24

Q3 2022
Bought 3.4% more+712.88K shares · 21.44M shares reported after the change
Filing context

Quarter-end price $43.76

Portfolio importance

How important was Pfizer in FMR LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q4 2024
Last reported rank#677Rank unavailable
Peak portfolio weight0.1%Q2 2022
Best historical rank#166Q2 2022
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$28.412026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$26.53Q4 2024

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

View Pfizer stock page →

Coverage is bounded to Fidelity’s top reported positions and material events rather than every security in each Form 13F. The consolidated FMR LLC filing includes multiple Fidelity investment managers. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.